Cumulative incidence curves of ILD among the medication groups after PSSW are shown in Figure 2A. The FXa inhibitor group had a higher risk of incident ILD (0.29 vs 0.17 per 100 patient-years; HR, 1.54 [95% CI, 1.22-1.94]; P < .001), whereas the dabigatran group had a nonsignificant difference in risk of incident ILD compared with the warfarin group after PSSW. This evidence concerns the gene F10 and interstitial lung disease.